The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Among the best performers in the Russell 2000 are 8 stocks all of which are up 200% or more ytd. And they all share something in common.
"They are all biotechs," said Cramer.
That's in part because, "biotech companies have growth prospects that are totally immune to the horror of a government shutdown, or the terror of an economic slowdown," noted the Mad Money host.
Which stocks have generated such outstanding returns? We thought you might be curious so we put together a list. It follows.
Up 504% year to date Acadia is developing a drug for psychosis caused by Parkinson's disease. "Acadia just reported some pretty positive phase 3 data, the company's launching a pivotal trial in the second half of next year, and they have enough cash to keep the business going until the FDA decides on whether to approve the drug in 2015," Cramer said. "That's a long way off, but for development stage biotechs like this one, the stocks trade on pipeline catalysts more than earnings or revenue estimates."
Up 463% for the year," Cramer said Celldex is in the biotech sweet spot. "It's an orphan drug developer," he noted, "one that targets a rare kidney disorder. Also the company's working on novel treatments for cancer—these are the two areas where you can charge hundreds of thousands of dollars a year for a drug once it gets approved. Celldex has a big catalyst coming next month when we get more phase 2 data on their potential brain tumor vaccine treatment. I like this one a great deal."
Up 370% ytd, Insys makes fast-acting painkillers for patients suffering from cancer. "Also, it's developing a synthetic medical marijuana to help with chemotherapy-induced nausea," Cramer said.
Read More from Mad Money with Jim Cramer
This isn't your father's shutdown, says Cramer
7 energy stocks on Cramer's watchlist
Market riskier than it appears?
Up 296% for the year, Keryx develops drugs for both kidney diseases and cancer. "Their flagship product, Zerenex for patients with end-stage renal disease, is currently in phase 3 trials—the data on this drug has been very positive, with fewer safety issues than the competition. Keryx has what we like to see: good clinical trial results with a drug in phase 3, the last phase before it can get approved and come to market," Cramer said.
Up 287% ytd, Clovis is developing a niche treatment for lung cancer. "The stock roared as the early stage data came out, and while it's pulled back lately as the company tried to put itself up for sale and failed, Clovis has even more in the pipeline and I'd come back to this one as they get further along," Cramer said.
Isis Pharma / Alnylam
Up 262% and 206% respectively ytd, Cramer groups these companies together because both treat disease by altering RNA. "I recommended Isis a year ago, then the company had some FDA issues. Since then his stock has quadrupled. Plus, it's not just this orphan cholesterol condition, Isis has 20 more drugs in the pipeline," Cramer said.
Up 255% ytd, "Aegerion is all about its drug for patients with super high cholesterol," Cramer said.
Up 268% year to date, NPS is also an orphan drug maker. "They have one drug on the market that's been approved for short-bowel syndrome and a lot more in the pipeline. When I recommended this thirteen months ago, many people seemed to hate it, yet now it feels like NPS goes up every day," Cramer said.
Call Cramer: 1-800-743-CNBC
Questions for Cramer? firstname.lastname@example.org
Questions, comments, suggestions for the "Mad Money" website? email@example.com